Drugs / 64Cu-DOTA-ECL1i
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04217057 | Feb 2020 → Feb 2023 | head and neck cancer | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT07659678 | Aug 2026 → Mar 2032 expected | head and neck squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05107596 Comparator | Nov 2018 → Nov 2025 | heart disorder | Washington University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-DOTA-ECL1i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107596 ↗ |
| Modality | Peptide | “based on the peptide, ECL1i (d(LGTFLKC)) and radiolabeled with 64Cu (64Cu-DOTA-ECL1i).” NCT04217057 ↗ |
| Route | Intravenous | “provided intravenously (IV)” NCT07659678 ↗ |
| Target | CCR2 | “CCR2 specific PET radiotracer” NCT04217057 ↗ |